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Primary mucoepidermoid tumors of the lung are rare entities. Synchronous primary malignancies of the lung involving
mucoepidermoid carcinoma and mucinous adenocarcinoma are even rarer and constitute a unique set of patient population. The
presentation, diagnosis and treatment strategies for this patient population are not well described. In most cases, the diagnosis of
synchronous primary lungmalignancy ismade after pathological examination of the resected lung specimen.Molecular and genetic
analysis is now being used to supplement the diagnosis of synchronous primary lung malignancies. In this work, we briefly discuss
the current state of knowledge of this unique combination of primary lung malignancies and describe the clinical presentation and
management of a patient with a rare combination of synchronous primary lung malignancies.
1. Introduction
Synchronous tumors are defined as two or more primary
neoplasms which are detected simultaneously. They differ
from metachronous tumors which are detected after an
intervening interval in their epidemiology, prognosis, and
management [1]. Precancerous lesions have been found at
a higher frequency in patients with multiple primary lung
cancers, but the genetic basis of such malignancies is yet
to be elucidated [2, 3]. It is possible that the development
of synchronous tumors is related more to environmental
exposure than to genetic predisposition as seen by the higher
incidence of synchronous tumors in workers exposed to
chromate [4]. However, there is some evidence to show that
genetic predisposition may play a role as multiple primary
lung cancers have been observed to be inherited in some
families [5]. Mutations in the p53 protein and allelic loss
of heterozygosity have been shown to be associated with
synchronous lung primary malignancies [6, 7]. Similar trend
with malignancies involving other organ systems has been
noted in patients with significant smoking history providing
credence to the hypothesis of field cancerization [8].
The diagnosis of true synchronous primary lung tumors
with different histologies has been difficult due to two
reasons: some patients with multiple primary lung tumors
with different histologies have been found to have identical
genetic changes suggesting a monoclonal origin and some
with patients with identical histologies have been found to
have different clonal origins [9–11]. This is complicated by
the fact that regional heterogeneity in tumor grade can be
observed in individual neoplasms and metastases may have
different tumor grades when compared to their primary
lesions [12]. Notably, imaging with fludeoxyglucose-positron
emission tomography (FDG-PET) has been noted to have
differences in uptake between different lesions in patients
with synchronous primary lung tumors [13]. However, the
clinical significance of this finding is not yet clear and has not
factored into treatment strategies. It is also possible that the
second primary malignancy may represent a metastasis from
an extrapulmonary site, and hence a thorough evaluation
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for other primaries is warranted [14]. Recent studies have
shown microsatellite analysis to be useful in differentiating
the multiple primary tumors from each other and also from
metastases [15].
Mucoepidermoid carcinoma is a common salivary gland
tumor which is often seen in the digestive system and the
respiratory tract.They were first described in 1945 by Stewart
et al. [16] in the salivary glands and in the tracheobronchial
tree by Smetana et al. [17]. Metastasis to the skeletal muscle,
pericardium, pleura, mediastinum, central nervous system,
gastrointestinal tract, and kidney has been described [18–21].
Primary pulmonary mucoepidermoid carcinomas are rare
and comprise 0.1-0.2% of primary lung malignancies [22].
Synchronousmucoepidermoid andmucinous adenocarcino-
mas are even rarer and there are very few reports in medical
literature which describe this combined entity.
2. Case Description
The patient is a 68-year-old lady with a past medical history
significant for hypertension, hyperlipidemia, and hypothy-
roidism who presented with complaints of lower abdominal
pain, diarrhea, and bright red blood per rectum. She was a
retired medical assistant who had quit smoking 3-4 weeks
prior to presentation after having smoked half pack a day
for 30 years. Her home medications included lisinopril,
simvastatin, aspirin, levothyroxine, and calcium and vitamin
D supplementation. Her review of systems was positive for
mild intermittent dry cough for the past 1.5 months. She
denied fever, chills, weight loss, productive cough, hemop-
tysis, night sweats, and changes in urinary habits. She had
unlimited exercise tolerance. Her physical examination in the
emergency department was unremarkable except for mild
tenderness to palpation over the lower abdomen.A computed
tomography (CT) scan of the abdomen showed sigmoid and
distal ascending colon colitis and incidentally identified a
right hilar mass. The mass was in the superior segment of
the right lower lobe and extended throughout the lower lobe
along the pulmonary vessels (Figure 1). The central part of
the mass was enhancing with hypodensity noted peripherally
suggestive of necrosis. The dominant portion of the mass
measured up to 6 cm transverse × 3.4 cm antero-posterior.
The tracheobronchial tree was found to be patent. An addi-
tional irregular, pleural based mass in the superior segment
of the right lower lobe was also identified which measured
3.9 cm transverse × 1.5 cm anteroposterior. An additional
pleural nodularity was noted in the inferior portion of the
right lower lobe. These findings were highly suggestive of
a right lower lobe malignancy. There was no significant
mediastinal, axillary, or hilar adenopathy noted except for a
subcarinal (9mm in short axis) and paratracheal lymph node
(5mm in short axis). She underwent bronchoscopy which
showed a friable exophytic endobronchial mass in the right
lower lobe at 1 cm from the bronchus intermedius, rest of
the anatomy normal. Bronchial brushings and endobronchial
biopsies × 3 were done. Immunostaining was positive for
mucicarmine, cytokeratin 7 (CK7), p63, focally positive
for cytokeratins 5,6 (CK 5,6), negative for synaptophysin,
Figure 1: Transverse section on a chest CT demonstrating the
presence of tumor lesions in the right middle and lower lobes.
thyroid transcription factor-1 (TTF-1), epidermal growth
factor receptor (EGFR), anaplastic lymphoma kinase (ALK)
and Napsin A (hematoxylin and eosin stains are shown in
Figures 2(a), 2(b), 2(c) and 2(d); immunostaining in Figures
3(a), 3(b), 3(c), and 3(d)). Positron emission tomography-
CT (PET-CT) showed a large focus of intense uptake in the
lower right lung medially, corresponding to a hilar mass
extending to the lower lobe seen on chest CT. No other
focal abnormalities are noted. She underwent right sided
Video-Assisted Thoracic Surgery (VATS) with right middle
and lower lobe bilobectomy with lymph node dissection.
Pathology showed 2 separate synchronous carcinomas (1st
tumor: nonsmall cell carcinoma, favor mucoepidermoid;
2nd tumor: mucinous adenocarcinoma). It was deemed that
the patient had 2 distinct primaries, both staged at T2N1.
Patient refused chemotherapy and has been doing well after
procedure.
3. Discussion
Patients with synchronous lung tumors have been shown
to have a worse prognosis when compared with patients
with lung malignancy at a similar stage [23, 24]. In the
past, pneumonectomy was associated with poor outcomes in
patients with multiple synchronous primary tumors, but this
trend has changed recently with aggressive surgical treatment
[25–27].This change has been attributed to a relative increase
in patient population with tumors at an earlier stage, possibly
linked to better detection techniques and increased surveil-
lance. While tumor size and lung function have been shown
to be independent predictors of survival, female gender seems
to be prognosticator for better outcomes [1]. Patients with
metachronous tumors on the other hand have been shown
to have a better survival rate when compared to patients with
synchronous lung primary malignancies [28, 29].
More than 50% of mucoepidermoid carcinomas have
a characteristic translocation between chromosomes 11q
and 19p [30, 31]. This rearrangement results in the forma-
tion of a fusion protein between mucoepidermoid carci-
noma translocated-1 (MECT1) and mastermind-like protein
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Figure 2: (a) Hematoxylin and eosin (H & E) stain showing endobronchial invasion of mucoepidermoid carcinoma. (b) H & E staining
showing the mucinous component of mucoepidermoid carcinoma. (c) H & E staining showing the solid component of mucoepidermoid
carcinoma. (d) H & E staining of mucinous adenocarcinoma.
2 (MAML2) genes [32]. MECT1 protein activates the c-
AMP response element-binding mediated transcription and
MAML-2 protein is a part of notch signaling [33, 34]. The
formation of this fusion protein has been shown to be
pathognomic for most of mucoepidermoid carcinomas [34,
35]. It was initially thought that presence of the fusion protein
was associated with better median survival, but recently it
has been shown that these patients did not have significant
disease-free survival despite better disease-specific survival
[30, 36]. The role of the fusion protein as a prognosticator
remains controversial [37, 38].
Surgical resection has been the mainstay of treatment
for low grade mucoepidermoid carcinomas but neodymium
yttrium aluminum garnet (Nd-YAG) laser has also been
used [39, 40]. Adjuvant chemotherapy has been reserved
for unresectable and advanced cases with limited success.
The mortality of high grade mucoepidermoid carcinomas
continues to remain high [41]. In rare caseswhere the tumor is
limited to the same lobe, surgical resection has been curative
for synchronous lesions involving bothmucoepidermoid and
adenocarcinoma [42].
4. Conclusion
The patient described here underwent surgery with an
excellent outcome. This case report serves to illustrate the
rarity of synchronous lung malignancies involving mucoepi-
dermoid carcinoma and mucinous adenocarcinoma. It also
demonstrates that early surgical intervention in patients with
synchronous lung malignancies at early stages may have
favorable outcomes despite the involvement ofmore than one
lung lobe.
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Figure 3: Immunohistochemistry showing staining with mucicarmine (a), CK 5, and 6 (b), p63 (c) and CK 7 (d).
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] T. Tanvetyanon, L. Robinson, K. E. Sommers et al., “Relation-
ship between tumor size and survival among patients with
resection of multiple synchronous lung cancers,” Journal of
Thoracic Oncology, vol. 5, no. 7, pp. 1018–1024, 2010.
[2] M. Seki and Y. Akasaka, “Multiple lung adenocarcinomas and
AAH treated by surgical resection,” Lung Cancer, vol. 55, no. 2,
pp. 237–240, 2007.
[3] G. Sozzi, M. Miozzo, U. Pastorino et al., “Genetic evidence for
an independent origin of multiple preneoplastic and neoplastic
lung lesions,” Cancer Research, vol. 55, no. 1, pp. 135–140, 1995.
[4] T. Uyama, Y. Monden, M. Tsuyuguchi, K. Harada, S. Kimura,
and T. Taniki, “Lung cancer in chromate workers: high-risk
group for multiple lung cancer,” Journal of Surgical Oncology,
vol. 41, no. 4, pp. 213–218, 1989.
[5] S. Haraguchi, K. Koizumi,M.Hioki, T. Hisayoshi, T. Hirata, and
K. Shimizu, “Hereditary factors in multiple primary malignan-
cies associated with lung cancer,” Surgery Today, vol. 37, no. 5,
pp. 375–378, 2007.
[6] K. Y. Chung, T. Mukhopadhyay, J. Kim et al., “Discordant p53
gene mutations in primary head and neck cancers and corre-
sponding second primary cancers of the upper aerodigestive
tract,” Cancer Research, vol. 53, no. 7, pp. 1676–1683, 1993.
[7] M. B. Reichel, H. Ohgaki, I. Petersen, and P. Kleihues, “p53
mutations in primary human lung tumors and theirmetastases,”
Molecular Carcinogenesis, vol. 9, no. 2, pp. 105–109, 1994.
[8] B. J. M. Braakhuis, M. P. Tabor, J. A. Kummer, C. R. Leemans,
and R. H. Brakenhoff, “A genetic explanation of slaughter’s con-
cept of field cancerization: evidence and clinical implications,”
Cancer Research, vol. 63, no. 8, pp. 1727–1730, 2003.
[9] X. Wang, M. Wang, G. T. MacLennan et al., “Evidence for
common clonal origin ofmultifocal lung cancers,” Journal of the
National Cancer Institute, vol. 101, no. 8, pp. 560–570, 2009.
[10] K. Hiroshima, T. Toyozaki, H. Kohno, H. Ohwada, and T.
Fujisawa, “Synchronous and metachronous lung carcinomas:
molecular evidence for multicentricity,” Pathology Interna-
tional, vol. 48, no. 11, pp. 869–876, 1998.
Case Reports in Oncological Medicine 5
[11] S. Shimizu, Y. Yatabe, T. Koshikawa et al., “High frequency of
clonally related tumors in cases of multiple synchronous lung
cancers as revealed by molecular diagnosis,” Clinical Cancer
Research, vol. 6, no. 10, pp. 3994–3999, 2000.
[12] R. R. Mercer, N. C. Lucas, A. N. Simmons et al., “Molecular
discrimination ofmultiple primary versusmetastatic squamous
cell cancers of the head/neck and lung,” Experimental and
Molecular Pathology, vol. 86, no. 1, pp. 1–9, 2009.
[13] B. G. Dijkman, O. C. J. Schuurbiers, D. Vriens et al., “The role
of18F-FDG PET in the differentiation between lung metastases
and synchronous second primary lung tumours,” European
Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no.
11, pp. 2037–2047, 2010.
[14] H. Rostad, T.-E. Strand, A. Naalsund, and J. Norstein, “Resected
synchronous primary malignant lung tumors: a population-
based study,” Annals of Thoracic Surgery, vol. 85, no. 1, pp. 204–
209, 2008.
[15] C. Shen, H. Xu, L. Liu, Y. Zhou, D. Chen, H. Du et al., “‘Unique
trend’ and “contradictory trend” in discrimination of primary
synchronous lung cancer and metastatic lung cancer,” BMC
Cancer, vol. 13, article 467, 2013.
[16] F. W. Stewart, F. W. Foote, andW. F. Becker, “Muco-epidermoid
tumors of salivary glands,” Annals of Surgery, vol. 122, no. 5, pp.
820–844, 1945.
[17] H. F. Smetana, L. Iverson, and L. L. Swan, “Bronchogenic
carcinoma, an analysis of 100 autopsy cases,” Military Surgeon,
vol. 111, no. 5, pp. 335–351, 1952.
[18] A. Singh, K. C. Pandey, and N. K. Pant, “Cavitary mucoepider-
moid carcinoma of lung with metastases in skeletal muscles as
presenting features: a case report and review of the literature,”
Journal of Cancer Research and Therapeutics, vol. 6, no. 3, pp.
350–352, 2010.
[19] S. H. Barsky, S. E. Martin, M. Matthews, A. Gazdar, and
J. C. Costa, “‘Low grade’ mucoepidermoid carcinoma of the
bronchus with “high grade” biological behavior,”Cancer, vol. 51,
no. 8, pp. 1505–1509, 1983.
[20] C. Ozlu, W. M. Christopherson, and J. D. Allen Jr., “Mucoepi-
dermoid tumors of the bronchus,” The Journal of Thoracic and
Cardiovascular Surgery, vol. 42, pp. 24–31, 1961.
[21] T. Tanvetyanon, V. Ratanatharathorn, and J. Leopairat,
“Mucoepidermoid carcinoma of the lung presenting as a
cavitary lesion,” Journal of the Medical Association of Thailand,
vol. 87, no. 8, pp. 988–991, 2004.
[22] D. L. Miller and M. S. Allen, “Rare pulmonary neoplasms,”
Mayo Clinic Proceedings, vol. 68, no. 5, pp. 492–498, 1993.
[23] R. J. Battafarano, S. D. Force, B. F. Meyers et al., “Benefits of
resection formetachronous lung cancer,”The Journal ofThoracic
and Cardiovascular Surgery, vol. 127, no. 3, pp. 836–842, 2004.
[24] M. T. M. van Rens, P. Zanen, A. Brutel de la Riviere, H. R. J.
Elbers, H. A. van Swieten, and J.M.M. van den Bosch, “Survival
in synchronous vs single lung cancer: upstaging better reflects
prognosis,” Chest, vol. 118, no. 4, pp. 952–958, 2000.
[25] D. Trousse, F. Barlesi, A. Loundou et al., “Synchronous mul-
tiple primary lung cancer: an increasing clinical occurrence
requiring multidisciplinary management,” Journal of Thoracic
and Cardiovascular Surgery, vol. 133, no. 5, pp. 1193–1200, 2007.
[26] F. Rea, A. Zuin, D. Callegaro, L. Bortolotti, G. Guanella, and
F. Sartori, “Surgical results for multiple primary lung cancers,”
European Journal of Cardio-Thoracic Surgery, vol. 20, no. 3, pp.
489–495, 2001.
[27] Y. C. Yu, P. K. Hsu, Y. C. Yeh et al., “Surgical results of
synchronous multiple primary lung cancers: similar to the
stage-matched solitary primary lung cancers?” The Annals of
Thoracic Surgery, vol. 96, no. 6, pp. 1966–1974, 2013.
[28] Y. Watanabe, J. Shimizu, M. Oda, Y. Tatsuzawa, Y. Hayashi, and
T. Iwa, “Second surgical intervention for recurrent and second
primary bronchogenic carcinomas,” Scandinavian Journal of
Thoracic and Cardiovascular Surgery, vol. 26, no. 1, pp. 73–78,
1992.
[29] S. A. Adebonojo, D. M. Moritz, and C. A. Danby, “The results
of modern surgical therapy for multiple primary lung cancers,”
Chest, vol. 112, no. 3, pp. 693–701, 1997.
[30] A. Behboudi, F. Enlund, M.Winnes et al., “Molecular classifica-
tion of mucoepidermoid carcinomas—prognostic significance
of the MECT1-MAML2 fusion oncogene,” Genes Chromosomes
& Cancer, vol. 45, no. 5, pp. 470–481, 2006.
[31] Y. Tirado, M. D. Williams, E. Y. Hanna, F. J. Kaye, J. G. Batsakis,
and A. K. El-Naggar, “CRTC1/MAML2 fusion transcript in
high grademucoepidermoid carcinomas of salivary and thyroid
glands and Warthin’s tumors: implications for histogenesis and
biologic behavior,”Genes Chromosomes & Cancer, vol. 46, no. 7,
pp. 708–715, 2007.
[32] A. Nordkvist, H. Gustafsson, M. Juberg-Ode, and G. Stenman,
“Recurrent rearrangements of 11q14-22 in mucoepidermoid
carcinoma,” Cancer Genetics and Cytogenetics, vol. 74, no. 2, pp.
77–83, 1994.
[33] V. Iourgenko, W. Zhang, C. Mickanin et al., “Identification of a
family of cAMP response element-binding protein coactivators
by genome-scale functional analysis in mammalian cells,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 100, no. 21, pp. 12147–12152, 2003.
[34] G. Tonon, S. Modi, L. Wu et al., “t(11;19)(q21;p13) translocation
in mucoepidermoid carcinoma creates a novel fusion product
that disrupts a Notch signaling pathway,” Nature Genetics, vol.
33, no. 2, pp. 208–213, 2003.
[35] A. K. El-Naggar, M. Lovell, A. M. Killary, G. L. Clayman,
and J. G. Batsakis, “A mucoepidermoid carcinoma of minor
salivary gland with t(11;19)(q21;p13.1) as the only karyotypic
abnormality,”Cancer Genetics and Cytogenetics, vol. 87, no. 1, pp.
29–33, 1996.
[36] R. R. Seethala, S. Dacic, K. Cieply, L. M. Kelly, and M. N.
Nikiforova, “A reappraisal of theMECT1/MAML2 translocation
in salivary mucoepidermoid carcinomas,” American Journal of
Surgical Pathology, vol. 34, no. 8, pp. 1106–1121, 2010.
[37] K. J. Jee, M. Persson, K. Heikinheimo et al., “Genomic profiles
and CRTC1-MAML2 fusion distinguish different subtypes of
mucoepidermoid carcinoma,”Modern Pathology, vol. 26, no. 2,
pp. 213–222, 2013.
[38] D. Bell and A. K. El-Naggar, “Molecular heterogeneity in
mucoepidermoid carcinoma: conceptual and practical implica-
tions,” Head and Neck Pathology, vol. 7, no. 1, pp. 23–27, 2013.
[39] C.-H. Li, S.-F. Huang, and H.-Y. Li, “Bronchoscopic Nd-
YAG laser surgery for tracheobronchial mucoepidermoid
carcinoma—a report of two cases,” International Journal of
Clinical Practice, vol. 58, no. 10, pp. 979–982, 2004.
[40] D.-Y. Kang, Y. S. Yoon,H. K. Kim et al., “Primary salivary gland-
type lung cancer: surgical outcomes,” Lung Cancer, vol. 72, no.
2, pp. 250–254, 2011.
6 Case Reports in Oncological Medicine
[41] G. Rossi, G. Sartori, A. Cavazza, and S. Tamberi, “Mucoepi-
dermoid carcinoma of the lung, response to EGFR inhibitors,
EGFR and K-RAS mutations, and differential diagnosis,” Lung
Cancer, vol. 63, no. 1, pp. 159–160, 2009.
[42] M. Kawakami, E. Tsujii, K. Tokitsu et al., “A case of synchronous
double cancer in the same pulmonary lobe,”KyobuGeka, vol. 47,
no. 13, pp. 1105–1109, 1994.
